{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T21:27:20Z","timestamp":1778016440085,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI20C1586"],"award-info":[{"award-number":["HI20C1586"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although immunotherapy has not yet been as successful in ovarian cancer (OC), it remains a potential therapeutic strategy. Preclinical models of OC are necessary to evaluate the efficacy of immuno-oncology (IO) drugs targeting human immune components but have been underutilized. Developing mouse models with a humanized (Hu) immune system can help understand the human immune response to IO drugs which have demonstrated limited effectiveness in OC patients. We established OC xenograft Hu-mouse models by intraperitoneally injecting luciferase-expressing SKOV-3 Luc and OVCAR-3 Luc OC cells into CD34\n                    <jats:sup>+<\/jats:sup>\n                    Hu-mice. Tumor growth was monitored through bioluminescence imaging (BLI). In the SKOV-3 Luc Hu-mouse model, we assessed the efficacy of PD-1 blockade with pembrolizumab. We observed the presence of human lymphocyte and myeloid cell subsets within the tumors, lymph nodes, blood, and spleens in these models. Notably, these tumors exhibited a high prevalence of tumor-infiltrating macrophages. Furthermore, we identified HDAC class I target genes, and genes associated with epithelial-mesenchymal transition (EMT) and fibroblasts in the tumors of Hu-mice treated with pembrolizumab. Our xenograft Hu-mouse model of OC provides a valuable tool for investigating the efficacy of IO drugs. The insights gained from this model offer useful information to explore potential mechanisms associated with unresponsive anti-PD-1 treatment in OC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-60501-z","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T11:01:45Z","timestamp":1716548505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transcriptome profiling and characterization of peritoneal metastasis ovarian cancer xenografts in humanized mice"],"prefix":"10.1038","volume":"14","author":[{"given":"Sung Wan","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ok-Ju","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Man","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Kyung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Wha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"60501_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"60501_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","volume":"32","author":"B Orr","year":"2018","unstructured":"Orr, B. & Edwards, R. P. Diagnosis and treatment of ovarian cancer. Hematol. Oncol. Clin. North Am. 32, 943\u2013964. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.010 (2018).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"60501_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","volume":"137","author":"KC Kurnit","year":"2021","unstructured":"Kurnit, K. C., Fleming, G. F. & Lengyel, E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet. Gynecol. 137, 108\u2013121. https:\/\/doi.org\/10.1097\/AOG.0000000000004173 (2021).","journal-title":"Obstet. Gynecol."},{"key":"60501_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre, L. A. et al. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 68, 284\u2013296. https:\/\/doi.org\/10.3322\/caac.21456 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"60501_CR5","doi-asserted-by":"publisher","first-page":"eabo3605","DOI":"10.1126\/scitranslmed.abo3605","volume":"14","author":"N Kirchhammer","year":"2022","unstructured":"Kirchhammer, N., Trefny, M. P., Auf der Maur, P., Laubli, H. & Zippelius, A. Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment. Sci. Transl. Med. 14, eabo3605. https:\/\/doi.org\/10.1126\/scitranslmed.abo3605 (2022).","journal-title":"Sci. Transl. Med."},{"key":"60501_CR6","doi-asserted-by":"publisher","first-page":"8052212","DOI":"10.1155\/2022\/8052212","volume":"2022","author":"L Yang","year":"2022","unstructured":"Yang, L., Ning, Q. & Tang, S. S. Recent advances and next breakthrough in immunotherapy for cancer treatment. J. Immunol. Res. 2022, 8052212. https:\/\/doi.org\/10.1155\/2022\/8052212 (2022).","journal-title":"J. Immunol. Res."},{"key":"60501_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060 (2018).","journal-title":"Science"},{"key":"60501_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.562315","volume":"11","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. Front. Oncol. 11, 562315. https:\/\/doi.org\/10.3389\/fonc.2021.562315 (2021).","journal-title":"Front. Oncol."},{"key":"60501_CR9","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102, 18538\u201318543. https:\/\/doi.org\/10.1073\/pnas.0509182102 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60501_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13048-021-00862-5","volume":"14","author":"J Zhu","year":"2021","unstructured":"Zhu, J., Yan, L. & Wang, Q. Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: A single-arm meta-analysis. J. Ovarian Res. 14, 112. https:\/\/doi.org\/10.1186\/s13048-021-00862-5 (2021).","journal-title":"J. Ovarian Res."},{"key":"60501_CR11","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501. https:\/\/doi.org\/10.1056\/NEJMc1713444 (2017).","journal-title":"N. Engl. J. Med."},{"key":"60501_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10080242","author":"GM Rodriguez","year":"2018","unstructured":"Rodriguez, G. M., Galpin, K. J. C., McCloskey, C. W. & Vanderhyden, B. C. The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers https:\/\/doi.org\/10.3390\/cancers10080242 (2018).","journal-title":"Cancers"},{"key":"60501_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1479-5876-12-36","volume":"12","author":"L Lu","year":"2014","unstructured":"Lu, L. et al. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 12, 36. https:\/\/doi.org\/10.1186\/1479-5876-12-36 (2014).","journal-title":"J. Transl. Med."},{"key":"60501_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omto.2022.03.005","volume":"25","author":"SK Gandham","year":"2022","unstructured":"Gandham, S. K., Rao, M., Shah, A., Trivedi, M. S. & Amiji, M. M. Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer. Mol. Ther. Oncolytics 25, 57\u201368. https:\/\/doi.org\/10.1016\/j.omto.2022.03.005 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"60501_CR15","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1038\/s41467-020-20140-0","volume":"11","author":"M Song","year":"2020","unstructured":"Song, M. et al. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat. Commun. 11, 6298. https:\/\/doi.org\/10.1038\/s41467-020-20140-0 (2020).","journal-title":"Nat. Commun."},{"key":"60501_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000416","author":"J Rios-Doria","year":"2020","unstructured":"Rios-Doria, J., Stevens, C., Maddage, C., Lasky, K. & Koblish, H. K. Characterization of human cancer xenografts in humanized mice. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2019-000416 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"60501_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41467-020-20600-7","volume":"12","author":"R Somasundaram","year":"2021","unstructured":"Somasundaram, R. et al. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat. Commun. 12, 346. https:\/\/doi.org\/10.1038\/s41467-020-20600-7 (2021).","journal-title":"Nat. Commun."},{"key":"60501_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041025","author":"WN Liu","year":"2020","unstructured":"Liu, W. N. et al. Establishment and characterization of humanized mouse NPC-PDX model for testing immunotherapy. Cancers https:\/\/doi.org\/10.3390\/cancers12041025 (2020).","journal-title":"Cancers"},{"key":"60501_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133092","author":"K Kleinmanns","year":"2022","unstructured":"Kleinmanns, K. et al. Humanized ovarian cancer patient-derived xenografts for improved preclinical evaluation of immunotherapies. Cancers https:\/\/doi.org\/10.3390\/cancers14133092 (2022).","journal-title":"Cancers"},{"key":"60501_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123818","author":"GA Rezniczek","year":"2020","unstructured":"Rezniczek, G. A. et al. Establishment of a mouse ovarian cancer and peritoneal metastasis model to study intraperitoneal chemotherapy. Cancers https:\/\/doi.org\/10.3390\/cancers12123818 (2020).","journal-title":"Cancers"},{"key":"60501_CR21","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1158\/1535-7163.MCT-13-0982","volume":"13","author":"X Xu","year":"2014","unstructured":"Xu, X. et al. Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: An in vivo study in orthotopic xenografts of nude mice. Mol. Cancer Ther. 13, 1729\u20131739. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0982 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"60501_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001237","author":"A Odunsi","year":"2020","unstructured":"Odunsi, A. et al. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-001237 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"60501_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: A fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360. https:\/\/doi.org\/10.1038\/nmeth.3317 (2015).","journal-title":"Nat. Methods"},{"key":"60501_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat. Biotechnol. 33, 290\u2013295. https:\/\/doi.org\/10.1038\/nbt.3122 (2015).","journal-title":"Nat. Biotechnol."},{"key":"60501_CR25","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/nprot.2016.095","volume":"11","author":"M Pertea","year":"2016","unstructured":"Pertea, M., Kim, D., Pertea, G. M., Leek, J. T. & Salzberg, S. L. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat. Protoc. 11, 1650\u20131667. https:\/\/doi.org\/10.1038\/nprot.2016.095 (2016).","journal-title":"Nat. Protoc."},{"key":"60501_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616 (2010).","journal-title":"Bioinformatics"},{"key":"60501_CR27","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60501_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782. https:\/\/doi.org\/10.1038\/s41587-019-0114-2 (2019).","journal-title":"Nat. Biotechnol."},{"key":"60501_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337 (2015).","journal-title":"Nat. Methods"},{"key":"60501_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1479-5876-12-4","volume":"12","author":"M Kobayashi","year":"2014","unstructured":"Kobayashi, M. et al. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J. Transl. Med. 12, 4. https:\/\/doi.org\/10.1186\/1479-5876-12-4 (2014).","journal-title":"J. Transl. Med."},{"key":"60501_CR31","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064\u20135074. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3271 (2014).","journal-title":"Clin. Cancer Res."},{"key":"60501_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1538\/expanim.19-0024","volume":"68","author":"M Nagatani","year":"2019","unstructured":"Nagatani, M. et al. Comparison of biological features between severely immuno-deficient NOD\/Shi-scid Il2rg(null) and NOD\/LtSz-scid Il2rg(null) mice. Exp. Anim. 68, 471\u2013482. https:\/\/doi.org\/10.1538\/expanim.19-0024 (2019).","journal-title":"Exp. Anim."},{"key":"60501_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310859","author":"A Pawlowska","year":"2023","unstructured":"Pawlowska, A. et al. Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms241310859 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"60501_CR34","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo, G. et al. Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin. Cancer Res. 25, 989\u2013999. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1390 (2019).","journal-title":"Clin. Cancer Res."},{"key":"60501_CR35","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1096\/fj.201700740R","volume":"32","author":"M Wang","year":"2018","unstructured":"Wang, M. et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 32, 1537\u20131549. https:\/\/doi.org\/10.1096\/fj.201700740R (2018).","journal-title":"FASEB J."},{"key":"60501_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-019-0518-z","volume":"7","author":"A Capasso","year":"2019","unstructured":"Capasso, A. et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J. Immunother. Cancer 7, 37. https:\/\/doi.org\/10.1186\/s40425-019-0518-z (2019).","journal-title":"J. Immunother. Cancer"},{"key":"60501_CR37","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3892\/ol.2020.11580","volume":"20","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Clinical significance of CD38 and CD101 expression in PD-1(+)CD8(+) T cells in patients with epithelial ovarian cancer. Oncol. Lett. 20, 724\u2013732. https:\/\/doi.org\/10.3892\/ol.2020.11580 (2020).","journal-title":"Oncol. Lett."},{"key":"60501_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.760225","volume":"12","author":"Q Quan","year":"2021","unstructured":"Quan, Q., Xiong, X., Wu, S. & Yu, M. Identification of immune-related key genes in ovarian cancer based on WGCNA. Front. Genet. 12, 760225. https:\/\/doi.org\/10.3389\/fgene.2021.760225 (2021).","journal-title":"Front. Genet."},{"key":"60501_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216121","volume":"559","author":"B Moran","year":"2023","unstructured":"Moran, B., Davern, M., Reynolds, J. V., Donlon, N. E. & Lysaght, J. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy. Cancer Lett. 559, 216121. https:\/\/doi.org\/10.1016\/j.canlet.2023.216121 (2023).","journal-title":"Cancer Lett."},{"key":"60501_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619236","volume":"11","author":"SA Mian","year":"2020","unstructured":"Mian, S. A., Anjos-Afonso, F. & Bonnet, D. Advances in human immune system mouse models for studying human hematopoiesis and cancer immunotherapy. Front. Immunol. 11, 619236. https:\/\/doi.org\/10.3389\/fimmu.2020.619236 (2020).","journal-title":"Front. Immunol."},{"key":"60501_CR41","first-page":"4568","volume":"10","author":"L Yin","year":"2020","unstructured":"Yin, L., Wang, X. J., Chen, D. X., Liu, X. N. & Wang, X. J. Humanized mouse model: A review on preclinical applications for cancer immunotherapy. Am. J. Cancer Res. 10, 4568\u20134584 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"60501_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001513","author":"N Park","year":"2020","unstructured":"Park, N. et al. Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-001513 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"60501_CR43","doi-asserted-by":"publisher","first-page":"21087","DOI":"10.1038\/s41598-021-00641-8","volume":"11","author":"I Katano","year":"2021","unstructured":"Katano, I. et al. Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody. Sci. Rep. 11, 21087. https:\/\/doi.org\/10.1038\/s41598-021-00641-8 (2021).","journal-title":"Sci. Rep."},{"key":"60501_CR44","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1002\/jcb.25547","volume":"117","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Real-time GFP intravital imaging of the differences in cellular and angiogenic behavior of subcutaneous and orthotopic nude-mouse models of human PC-3 prostate cancer. J. Cell Biochem. 117, 2546\u20132551. https:\/\/doi.org\/10.1002\/jcb.25547 (2016).","journal-title":"J. Cell Biochem."},{"key":"60501_CR45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ygyno.2006.03.030","volume":"103","author":"H Sallinen","year":"2006","unstructured":"Sallinen, H. et al. A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol. Oncol. 103, 315\u2013320. https:\/\/doi.org\/10.1016\/j.ygyno.2006.03.030 (2006).","journal-title":"Gynecol. Oncol."},{"key":"60501_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110451","volume":"121","author":"J Hye Jeong","year":"2023","unstructured":"Hye Jeong, J. et al. Orthotopic model of pancreatic cancer using CD34(+) humanized mice and generation of tumor organoids from humanized tumors. Int. Immunopharmacol. 121, 110451. https:\/\/doi.org\/10.1016\/j.intimp.2023.110451 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"60501_CR47","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.21873\/invivo.12485","volume":"35","author":"Y Ko","year":"2021","unstructured":"Ko, Y., Jeong, Y. H., Seo, J. H. & Lee, J. A. Development of a bioluminescent human osteosarcoma model in humanized NSG mice: A pilot study. In Vivo 35, 2151\u20132157. https:\/\/doi.org\/10.21873\/invivo.12485 (2021).","journal-title":"In Vivo"},{"key":"60501_CR48","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ymthe.2004.08.013","volume":"10","author":"TJ Shaw","year":"2004","unstructured":"Shaw, T. J., Senterman, M. K., Dawson, K., Crane, C. A. & Vanderhyden, B. C. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 10, 1032\u20131042. https:\/\/doi.org\/10.1016\/j.ymthe.2004.08.013 (2004).","journal-title":"Mol. Ther."},{"key":"60501_CR49","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/j.1349-7006.2010.01652.x","volume":"101","author":"K Takaishi","year":"2010","unstructured":"Takaishi, K. et al. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 101, 2128\u20132136. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01652.x (2010).","journal-title":"Cancer Sci."},{"key":"60501_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2017.07.007","volume":"147","author":"X Yuan","year":"2017","unstructured":"Yuan, X. et al. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Gynecol. Oncol. 147, 181\u2013187. https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.007 (2017).","journal-title":"Gynecol. Oncol."},{"key":"60501_CR51","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/cmi.2015.57","volume":"12","author":"S Zhang","year":"2015","unstructured":"Zhang, S. et al. Analysis of CD8+ Treg cells in patients with ovarian cancer: A possible mechanism for immune impairment. Cell Mol. Immunol. 12, 580\u2013591. https:\/\/doi.org\/10.1038\/cmi.2015.57 (2015).","journal-title":"Cell Mol. Immunol."},{"key":"60501_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie, Y., Tang, F., Wei, Y. Q. & Wei, X. W. Immunosuppressive cells in cancer: Mechanisms and potential therapeutic targets. J. Hematol. Oncol. 15, 61. https:\/\/doi.org\/10.1186\/s13045-022-01282-8 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"60501_CR53","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555. https:\/\/doi.org\/10.1038\/s41586-019-1922-8 (2020).","journal-title":"Nature"},{"key":"60501_CR54","doi-asserted-by":"publisher","first-page":"795","DOI":"10.4161\/cbt.6.5.4007","volume":"6","author":"D Khabele","year":"2007","unstructured":"Khabele, D. et al. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy. Cancer Biol. Ther. 6, 795\u2013801. https:\/\/doi.org\/10.4161\/cbt.6.5.4007 (2007).","journal-title":"Cancer Biol. Ther."},{"key":"60501_CR55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00262-017-2091-y","volume":"67","author":"D Briere","year":"2018","unstructured":"Briere, D. et al. The class I\/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol. Immunother. 67, 381\u2013392. https:\/\/doi.org\/10.1007\/s00262-017-2091-y (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"60501_CR56","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","volume":"40","author":"X Li","year":"2021","unstructured":"Li, X. et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene 40, 1836\u20131850. https:\/\/doi.org\/10.1038\/s41388-020-01636-x (2021).","journal-title":"Oncogene"},{"key":"60501_CR57","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1038\/s41598-023-28480-9","volume":"13","author":"PM Szabo","year":"2023","unstructured":"Szabo, P. M. et al. Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment. Sci. Rep. 13, 3051. https:\/\/doi.org\/10.1038\/s41598-023-28480-9 (2023).","journal-title":"Sci. Rep."},{"key":"60501_CR58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191094","author":"A Hussain","year":"2020","unstructured":"Hussain, A. et al. Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20191094 (2020).","journal-title":"J. Exp. Med."},{"key":"60501_CR59","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.ajpath.2015.12.029","volume":"186","author":"R Murakami","year":"2016","unstructured":"Murakami, R. et al. Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes. Am. J. Pathol. 186, 1103\u20131113. https:\/\/doi.org\/10.1016\/j.ajpath.2015.12.029 (2016).","journal-title":"Am. J. Pathol."},{"key":"60501_CR60","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","volume":"100","author":"M Ito","year":"2002","unstructured":"Ito, M. et al. NOD\/SCID\/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood 100, 3175\u20133182. https:\/\/doi.org\/10.1182\/blood-2001-12-0207 (2002).","journal-title":"Blood"},{"key":"60501_CR61","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3892\/ijo.2017.4115","volume":"51","author":"J Guo","year":"2017","unstructured":"Guo, J. et al. Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study. Int. J. Oncol. 51, 1199\u20131208. https:\/\/doi.org\/10.3892\/ijo.2017.4115 (2017).","journal-title":"Int. J. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60501-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60501-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60501-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T11:10:26Z","timestamp":1716549026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60501-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["60501"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-60501-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.10.27.563867","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11894"}}